“…To this end, apps are increasingly utilized in the treatment of SMI in a variety of ways (e.g., stand-alone interventions, symptom monitoring, adjunctive therapeutic support) with demonstrated feasibility and efficacy ( Batra et al, 2017 ; Ben-Zeev et al, 2018 ; Bucci et al, 2018 ; Depp et al, 2016 ; Eisner et al, 2019 ; Firth and Torous, 2015 ; Fortuna et al, 2018 ; Liu et al, 2019 ). Yet, there is variable engagement with apps among users with SMI (e.g., a small subset of users often account for a large proportion of app engagement) and the real-world uptake of smartphone apps by clinics and users remains relatively low ( Torous et al, 2017 ; Torous et al, 2018 ), which is concerning given that app engagement is linked with improved outcomes ( Ben-Zeev et al, 2018 ; Best et al, 2019 ; Browne et al, 2021 ; Harvey et al, 2020 ). Therefore, knowledge of the putative barriers to app engagement in this population is necessary to guide strategies for facilitating adequate uptake.…”